G
Gaia Kiru
Researcher at Imperial College London
Publications - 5
Citations - 377
Gaia Kiru is an academic researcher from Imperial College London. The author has contributed to research in topics: Medicine & Perindopril. The author has an hindex of 3, co-authored 3 publications receiving 137 citations.
Papers
More filters
Journal ArticleDOI
EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study
Kausik K. Ray,Bart Molemans,W. Marieke Schoonen,Periklis Giovas,Sarah Bray,Gaia Kiru,Jennifer Murphy,Maciej Banach,Maciej Banach,Maciej Banach,Stefano De Servi,Dan Gaita,Ioanna Gouni-Berthold,G. Kees Hovingh,Jacek Jerzy Jozwiak,J. Wouter Jukema,Róbert Gábor Kiss,Serge Kownator,Helle K. Iversen,Vincent Maher,Luis Masana,Alexander Parkhomenko,André Peeters,Piers Clifford,Katarina Raslova,Peter Siostrzonek,Stefano Romeo,Stefano Romeo,Stefano Romeo,Dimitrios Tousoulis,Charalambos Vlachopoulos,Michal Vrablík,Alberico L. Catapano,Neil R Poulter,DA Vinci study +34 more
TL;DR: In this article, the authors provide contemporary data on the implementation of European guideline recommendations for lipid-lowering therapies (LLTs) across different settings and populations and how this impacts low-density lipoprotein cholesterol (LDL-C) goal achievement.
Journal ArticleDOI
An evaluation of the effect of an angiotensin-converting enzyme inhibitor on the growth rate of small abdominal aortic aneurysms: a randomized placebo-controlled trial (AARDVARK)
TL;DR: Small abdominal aortic aneurysms growth rates were lower than anticipated, but there was no significant impact of perindopril compared with placebo or placebo and amlodipine, combined despite more effective BP lowering.
Journal ArticleDOI
An evaluation of the effect of an angiotensin-converting enzyme inhibitor on the growth rate of small abdominal aortic aneurysms: a randomised placebo-controlled trial (AARDVARK).
TL;DR: A three-arm, multicentre, single-blind, randomised placebo-controlled trial to investigate whether or not the ACE-I perindopril reduces small AAA growth rate and to compare the repeatability of measurement of internal and external aneurysm diameters.
Journal ArticleDOI
Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI
Antonio J. Vallejo-Vaz,Sarah C Bray,Guillermo Villa,Julia Brandts,Gaia Kiru,Jennifer Murphy,Maciej Banach,Stefano De Servi,Dan Gaita,Ioanna Gouni-Berthold,G. Kees Hovingh,Jacek Jerzy Jozwiak,J. Wouter Jukema,Robert Gabor Kiss,Serge Kownator,Helle K. Iversen,V. Maher,Luis Masana,Alexander Parkhomenko,André Peeters,Piers Clifford,Katarina Raslova,Peter Siostrzonek,Stefano Romeo,Dimitris Tousoulis,Charalambos Vlachopoulos,Michal Vrablík,Alberico L. Catapano,Neil R Poulter,Kausik K. Ray +29 more
TL;DR: In this paper , the authors compared the 2018 American College of Cardiology/American Heart Association (ACC/AHA) and 2019 ESC/EAS guidelines for patients with atherosclerotic cardiovascular disease (ASCVD) (< 70 vs. < 55 mg/dl, respectively).
Journal ArticleDOI
Global blood pressure screening during the COVID-19 pandemic: results from the May Measurement Month 2021 campaign.
Thomas Beaney,Wei Wang,Markus P. Schlaich,Aletta E. Schutte,George S. Stergiou,Luis Alcocer,Jafar Alsaid,Rafael Hernández-Hernández,Jacek Jerzy Jozwiak,Nadia A. Khan,Gaia Kiru,Augustine N. Odili,Wook Bum Pyun,Cesar A. Romero,Jiguang Wang,Neil R Poulter +15 more
TL;DR: In this paper , the authors assessed the global burden of these rates during the COVID-19 pandemic and concluded that the high yield of untreated or inadequately treated hypertension in MMM 2021 confirms the need for systematic BP screening where it does not currently exist.